| 8.12 -0.37 (-4.36%) | 10-15 12:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.64 | 1-year : | 11.43 |
| Resists | First : | 9.11 | Second : | 9.78 |
| Pivot price | 8.82 |
|||
| Supports | First : | 8.02 | Second : | 6.67 |
| MAs | MA(5) : | 8.44 |
MA(20) : | 8.83 |
| MA(100) : | 6.36  |
MA(250) : | 5.52 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 19.5 |
D(3) : | 22 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 11.12 | Low : | 2.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BNR ] has closed above bottom band by 6.1%. Bollinger Bands are 40.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.51 - 8.56 | 8.56 - 8.6 |
| Low: | 8.06 - 8.12 | 8.12 - 8.18 |
| Close: | 8.39 - 8.49 | 8.49 - 8.57 |
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
Wed, 24 Sep 2025
Major Breast Cancer Diagnostic Breakthrough: Burning Rock's OncoScreen Plus CDx System Gets Japan Green Light - Stock Titan
Mon, 08 Sep 2025
Burning Rock Biotech Loss Shrinks In Q2 - Nasdaq
Mon, 08 Sep 2025
Burning Rock Reports Second Quarter 2025 Financial Results - GlobeNewswire
Wed, 16 Jul 2025
3 Promising Penny Stocks With Market Caps Over $40M - simplywall.st
Fri, 06 Jun 2025
Burning Rock Reports First Quarter 2025 Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 9 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 42.1 (%) |
| Shares Short | 39 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -1.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 52.4 |
| Profit Margin | -26.2 % |
| Operating Margin | -7.8 % |
| Return on Assets (ttm) | -7.6 % |
| Return on Equity (ttm) | -22.6 % |
| Qtrly Rev. Growth | 9.6 % |
| Gross Profit (p.s.) | 42.83 |
| Sales Per Share | 59.39 |
| EBITDA (p.s.) | -11.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -79 (M) |
| Levered Free Cash Flow | 95 (M) |
| PE Ratio | -4.33 |
| PEG Ratio | 0 |
| Price to Book value | 0.15 |
| Price to Sales | 0.13 |
| Price to Cash Flow | -0.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|